EP Patent

EP4547665A1 — Solid forms of a nucleoside analogue and uses thereof

Assigned to Gilead Sciences Inc · Expires 2025-05-07 · 1y expired

What this patent protects

The present disclosure relates to solid forms (e.g. crystalline forms, solvates, and crystalline forms thereof) of a compound which is ((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl neopentyl carbonate, which is useful…

USPTO Abstract

The present disclosure relates to solid forms (e.g. crystalline forms, solvates, and crystalline forms thereof) of a compound which is ((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl neopentyl carbonate, which is useful in the treatment of treating viral infections, for example paramyxoviridae , pneumoviridae , picornaviridae , flaviviridae , filoviridae , arenaviridae , orthomyxovirus , and coronaviridae infections.

Drugs covered by this patent

Patent Metadata

Patent number
EP4547665A1
Jurisdiction
EP
Classification
—
Expires
2025-05-07
Drug substance claim
No
Drug product claim
No
Assignee
Gilead Sciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.